FTC insists generics ANI and Novitium divest IP before merger

The Federal Trade Commission (FTC) has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

MedTech

Abbott clinches 18-country PI in glucose monitoring feud

9 September 2026 The UPC has handed the medical device company a significant win over continuous glucose monitoring tech, granting a broad provisional injunction after finding that SiBio’s rival system was likely to infringe its European patent.

Careers

UK firm hires head of IP with commercial and technical nous

8 September 2026 With technical specialisms including nucleic acid technologies, biological therapeutics and vaccines, and diagnostics and biological assays, the new hire adds a life sciences patent specialism to the firm’s growing IP practice.

Pharma

Italy’s Biofer falls short in Fed Circ appeal over key claim wording

7 September 2026 A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.

More features

Abbott clinches 18-country PI in glucose monitoring feud

UK firm hires head of IP with commercial and technical nous

Italy’s Biofer falls short in Fed Circ appeal over key claim wording

G 1/25: EPO settles controversial patent description question

California votes for law to restrict use of genAI by lawyers

Sun Pharma import ban back in force after Squires intervention

10x Genomics wins latest round in Parse patent dispute

White & Case life sciences co-leader moves firms

FTC insists generics ANI and Novitium divest IP before merger

More on this story

Editor's picks

Editor's picks

More features